Rafael Holdings (RFL) Exchange Rate Effect (2017 - 2026)
Rafael Holdings' (RFL) quarterly Exchange Rate Effect came in at $24000.0 in Q2 2026, down 52.0% quarter-over-quarter from $50000.0 in Q1 2026.
Analysis
Rafael Holdings (RFL) Exchange Rate Effect (2017 - 2026) Analysis & Trends
Rafael Holdings (RFL) has reported Exchange Rate Effect for 10 consecutive years, with $24000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Exchange Rate Effect changed N/A year-over-year to $24000.0 in Q2 2026; TTM through Apr 2026 was $109000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $153000.0, up 795.45% from the prior year.
- Exchange Rate Effect was $24000.0 for Q2 2026 at Rafael Holdings, down from $50000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $191000.0 in Q1 2024 and troughed at -$276000.0 in Q2 2023.
- A 5-year average of -$24466.7 and a median of $24000.0 in 2026 frame the typical range for Exchange Rate Effect.
- Across the five-year window, Exchange Rate Effect tumbled 4700.0% in 2022 and surged 3700.0% in 2025, its largest moves.
- Over 5 years, Exchange Rate Effect stood at -$92000.0 in 2022, then tumbled by 105.43% to -$189000.0 in 2023, then surged by 99.47% to -$1000.0 in 2024, then surged by 3700.0% to $36000.0 in 2025, then plunged by 33.33% to $24000.0 in 2026.
- The last three Exchange Rate Effect figures came in at $24000.0 (Q2 2026), $50000.0 (Q1 2026), and $36000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -19.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -3.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -300,000.00 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -2.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -2.45 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -3.40 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 315,000.00 |
| 10 | Rafael Holdings | 117.57 Mn | 117.57 Mn | 171,000.00 | 24,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 24,000.00 |
| Jan 31, 2026 | 50,000.00 |
| Oct 31, 2025 | 36,000.00 |
| Oct 31, 2024 | -1,000.00 |
| Jul 31, 2024 | 26,000.00 |
| Apr 30, 2024 | -50,000.00 |
| Jan 31, 2024 | 191,000.00 |
| Oct 31, 2023 | -189,000.00 |
| Jul 31, 2023 | 133,000.00 |
| Apr 30, 2023 | -276,000.00 |
| Jan 31, 2023 | 89,000.00 |
| Oct 31, 2022 | -92,000.00 |
| Jul 31, 2022 | -146,000.00 |
| Apr 30, 2022 | -211,000.00 |
| Jan 31, 2022 | 49,000.00 |
| Oct 31, 2021 | 2,000.00 |
| Jul 31, 2021 | 97,000.00 |
| Apr 30, 2021 | 7,000.00 |
| Jan 31, 2021 | 21,000.00 |
| Oct 31, 2020 | -3,000.00 |